jobs

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Pulse Biosciences, Inc.

< Previous 1 2 Next >
Pulse Biosciences Reports Business Updates and Third Quarter 2023 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
UPDATE Pulse Biosciences Announces New Time for Third Quarter 2023 Financial Results Conference Call
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences Schedules Third Quarter 2023 Financial Results Conference Call for November 13, 2023
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences Appoints Dr. Niv Ad as Chief Science Officer, Cardiac Surgery
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences Announces Collaboration with CardioNXT for nsPFA First-in-Human Atrial Fibrillation Study
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences’ Nanosecond Pulsed Field Ablation (nsPFA™) Circumferential Catheter System to be Featured in a Presentation at the Global EP Summit
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences’ First Study in a Surgical Application of Nanosecond Pulsed Field Ablation (nsPFA) Technology to be Featured in Two Poster Presentations at the American Thyroid Association Annual Meeting
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences to Present at Gilmartin Group Emerging Growth Showcase
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences Clarifies Details of Recent S-3 Filing
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences Reports Business Updates and Second Quarter 2023 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences Schedules Second Quarter 2023 Financial Results Conference Call for August 10, 2023
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences’ Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm 2023 Annual Meeting
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences Reports Business Updates and First Quarter 2023 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences, Inc. Announces Planned Redemption of Warrants
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences, Inc. Appoints Dr. Gan Dunnington as Chief Medical Officer
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences Announces $65 Million Private Placement
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences Schedules First Quarter 2023 Financial Results Conference Call for May 11, 2023
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences Reports Fourth Quarter & Full Year 2022 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences Schedules Fourth Quarter & Full Year 2022 Financial Results Conference Call for March 30, 2023
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences Reports Third Quarter 2022 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences Schedules Third Quarter 2022 Financial Results Conference Call for November 10, 2022
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences Announces Positive Clinical Data on Nano-Pulse Stimulation Procedure for Low-Risk Basal Cell Carcinoma Lesions
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences Announces FDA 510(k) Clearance for the Treatment of Sebaceous Hyperplasia
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences Announces Strategic Change of Focus in Support of Significant Additional Opportunities for medicinal related Nano-Pulse Stimulation
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences Reports Second Quarter 2022 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences Receives FDA 510(k) Clearance of Expanded Energy Settings for use with the CellFX® System
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences Schedules Second Quarter 2022 Financial Results Conference Call for August 10, 2022
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences, Inc. Announces the Closing of Its Rights Offering
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering
From Pulse Biosciences, Inc.
Via Business Wire
Tickers PLSE
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

More ways to get to us

Medicine Hat News Twitter Twitter
Medicine Hat News Facebook Facebook
Medicine Hat News Instagram Instagram
Medicine Hat News YouTube YouTube
Medicine Hat News Tumblr Tumblr

About Us

Contact the Medicine Hat News

922 Allowance Ave SE
Medicine Hat, AB T1A 3G7

Office hours: 8:30 a.m.-4:30 p.m. Monday to Friday, closed Saturday Sunday and statutory holidays.

[P] 403.527.1101
[F] 403-527-0737

Print Advertising: 403.528.5659
National Advertising: 403.528.5766
Online Advertising: 403.528.5698
Classifieds: 403.526.7653

© 1996-2024 The Medicine Hat News